New York congressman resigns ahead of insider trading plea

Reuters

Published Sep 30, 2019 07:13PM ET

New York congressman resigns ahead of insider trading plea

New York congressman resigns ahead of insider trading plea

By Brendan Pierson and Richard Cowan

NEW YORK/WASHINGTON (Reuters) - Chris Collins, a Republican U.S. congressman from New York state, resigned on Monday ahead of his expected guilty plea in a criminal insider trading case.

A senior Democratic aide speaking on condition of anonymity said Monday that the office of U.S. House of Representatives Speaker Nancy Pelosi had received Collins' letter of resignation, and that it would become effective Tuesday.

Collins, 69, is scheduled to appear in Manhattan federal that day to enter his guilty plea, court records show. Collins' son, Cameron Collins, and another man, Stephen Zarsky, are also scheduled to plead guilty in the case on Thursday.

A spokesman for U.S. Attorney Geoffrey Berman, whose office is prosecuting the case, declined to comment, as did Mauro Wolfe, a lawyer for Zarsky.

Lawyers for Chris and Cameron Collins could not immediately be reached.

Chris Collins, an early supporter of President Donald Trump, represents New York's 27th Congressional District, which includes areas surrounding Buffalo and Rochester. He won reelection last November, three months after he was criminally charged.

The criminal case relates to Australian biotechnology company Innate Immunotherapeutics Ltd, a company for which Chris Collins sat on the board and held a 16.8% stake.

Prosecutors allege that in June 2017, while attending the congressional picnic at the White House, Collins learned in an email from Innate's chief executive that a clinical trial for its proposed multiple sclerosis drug MIS416 had failed.

Collins immediately told the trial failure news to his son, who in turn told his fiancée, Lauren Zarsky, and her parents, Dorothy and Stephen Zarsky, prosecutors allege.

Chris Collins did not trade his own Innate stock, which lost millions of dollars in value. Prosecutors said the congressman was "virtually precluded" from trading in part because he already faced a congressional ethics probe over Innate.

However, prosecutors said others used the insider information to avoid more than $768,000 in losses when Innate's share price plunged 92% after news of the drug's failure became public.

© Reuters. FILE PHOTO: U.S. Representative Chris Collins is interviewed during the 2017 "Congress of Tomorrow" Joint Republican Issues Conference in Philadelphia, Pennsylvania, U.S.

Lauren and Dorothy Zarsky were not criminally charged, but reached civil settlements with the U.S. Securities and Exchange Commission.

Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Sign out
Are you sure you want to sign out?
NoYes
CancelYes
Saving Changes